JP2024516972A - Ｒａｆ阻害薬による癌の処置 - Google Patents

Ｒａｆ阻害薬による癌の処置 Download PDF

Info

Publication number
JP2024516972A
JP2024516972A JP2023565207A JP2023565207A JP2024516972A JP 2024516972 A JP2024516972 A JP 2024516972A JP 2023565207 A JP2023565207 A JP 2023565207A JP 2023565207 A JP2023565207 A JP 2023565207A JP 2024516972 A JP2024516972 A JP 2024516972A
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
braf
compound
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565207A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022226261A5 (https=
JP2024516972A5 (https=
Inventor
フラノヴィッチ，アレクサンドラ
マーティン，エリック
エル．ジー． ミラー，ニコル
マーフィー，エリック
トーマス ウィリアムズ，リチャード
コバヤシ，ケン
Original Assignee
キネート バイオファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キネート バイオファーマ インク． filed Critical キネート バイオファーマ インク．
Publication of JP2024516972A publication Critical patent/JP2024516972A/ja
Publication of JPWO2022226261A5 publication Critical patent/JPWO2022226261A5/ja
Publication of JP2024516972A5 publication Critical patent/JP2024516972A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023565207A 2021-04-23 2022-04-22 Ｒａｆ阻害薬による癌の処置 Pending JP2024516972A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178922P 2021-04-23 2021-04-23
US63/178,922 2021-04-23
PCT/US2022/025875 WO2022226261A1 (en) 2021-04-23 2022-04-22 Treatment of cancer with a raf inhibitor

Publications (3)

Publication Number Publication Date
JP2024516972A true JP2024516972A (ja) 2024-04-18
JPWO2022226261A5 JPWO2022226261A5 (https=) 2025-04-25
JP2024516972A5 JP2024516972A5 (https=) 2025-04-25

Family

ID=83722622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565207A Pending JP2024516972A (ja) 2021-04-23 2022-04-22 Ｒａｆ阻害薬による癌の処置

Country Status (12)

Country Link
US (2) US11918587B2 (https=)
EP (1) EP4326256A4 (https=)
JP (1) JP2024516972A (https=)
KR (1) KR20240000534A (https=)
CN (1) CN117561057A (https=)
AU (1) AU2022261117A1 (https=)
BR (1) BR112023021913A2 (https=)
CA (1) CA3216104A1 (https=)
IL (1) IL307908A (https=)
MX (1) MX2023012515A (https=)
TW (1) TW202308645A (https=)
WO (1) WO2022226261A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN117561057A (zh) 2021-04-23 2024-02-13 金耐特生物制药公司 用raf抑制剂治疗癌症
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
AU2024322235A1 (en) * 2023-08-09 2026-02-26 Pierre Fabre Medicament Treatment of cancer with a raf inhibitor
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025145207A1 (en) * 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
CA2714700C (en) 2008-02-22 2013-07-30 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010078408A1 (en) 2008-12-30 2010-07-08 Biogen Idec Ma Inc. Heteroaryl compounds useful as raf kinase inhibitors
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
DK3366293T3 (da) 2012-06-07 2020-06-15 Deciphera Pharmaceuticals Llc Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10167279B2 (en) 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
JP2022525885A (ja) 2019-03-22 2022-05-20 キネート バイオファーマ インク． Ｒａｆキナーゼの阻害剤
US10927111B2 (en) * 2019-05-03 2021-02-23 Kinnate Biopharma Inc. Inhibitors of RAF kinases
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
US11407737B2 (en) * 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN117529313A (zh) 2021-04-23 2024-02-06 金耐特生物制药公司 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐
CN117561057A (zh) * 2021-04-23 2024-02-13 金耐特生物制药公司 用raf抑制剂治疗癌症

Also Published As

Publication number Publication date
EP4326256A1 (en) 2024-02-28
US11918587B2 (en) 2024-03-05
BR112023021913A2 (pt) 2024-01-16
MX2023012515A (es) 2023-12-15
WO2022226261A1 (en) 2022-10-27
EP4326256A4 (en) 2025-03-19
IL307908A (en) 2023-12-01
TW202308645A (zh) 2023-03-01
US12569496B2 (en) 2026-03-10
CA3216104A1 (en) 2022-10-27
US20240325403A1 (en) 2024-10-03
AU2022261117A1 (en) 2023-11-23
US20230255977A1 (en) 2023-08-17
CN117561057A (zh) 2024-02-13
KR20240000534A (ko) 2024-01-02

Similar Documents

Publication Publication Date Title
JP2024516972A (ja) Ｒａｆ阻害薬による癌の処置
JP6742391B2 (ja) 併用療法
Zhao et al. The clinical development of MEK inhibitors
AU2020259565A1 (en) Quinoline compound or pharmaceutically acceptable salt thereof for treating Ewing's sarcoma
JP2022509262A (ja) 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント
TW202227083A (zh) 用於外顯子-20插入的突變egfr癌症之治療療法
JP2023534991A (ja) 変異型ｉｄｈ１阻害剤、デオキシアデノシン類似体、及び白金剤を用いた併用療法
JP2022521173A (ja) 癌治療
JP2024546101A (ja) Ｆｇｆｒキナーゼ阻害剤を用いた癌の治療
US20230233567A1 (en) Belvarafenib for use in cancer treatment
WO2024220427A1 (en) Treatment of cancer with a mek kinase inhibitor
Sun et al. Systemic therapy for mutation-driven NSCLC
TW202406552A (zh) 用於治療癌症之ｅｇｆｒ抑制劑
KR20230165795A (ko) 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법
AU2024322235A1 (en) Treatment of cancer with a raf inhibitor
US20250339412A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
HK40087830A (zh) 用於癌症治疗的贝伐非尼
US20250275978A1 (en) Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
WO2025010287A2 (en) Mek immune oncology inhibitors and therapeutic uses thereof
WO2025162446A1 (zh) 一种egfr抑制剂的用途
JP2026501284A (ja) リプレチニブを用いて消化管間質腫瘍を治療する方法
WO2019223672A1 (zh) 用于治疗非小细胞肺癌的喹啉衍生物
EA040191B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250416